Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

Cancer Chemotherapy and Pharmacology

Volumn 79, Issue 1, 2017, Pages 29-36

  Nakamura, Masato ^a   Aoyama, Toru ^b   Ishibashi, Keiichiro ^c   Tsuji, Akihito ^d   Takinishi, Yasutaka ^e   Shindo, Yoshiaki ^f   Sakamoto, Junichi ^g   Oba, Koji ^h   Mishima, Hideyuki ⁱ  

^a Aizawa Hospital   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f NAKADORI GENERAL HOSPITAL   (Japan)

^g Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cetuximab; Colorectal cancer; KRAS G13D

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; BILIRUBIN; CETUXIMAB; CREATINE; IRINOTECAN; K RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CODON; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; CODON; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPHATIC SYSTEM METASTASIS; MALE; MEDICATION COMPLIANCE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PARONYCHIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; CODON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84996477397     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3203-7     Document Type: Article

References (16)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914
3. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865
4. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825–3829
5. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
7. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346
8. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF et al (2009) American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096
9. US Food and Drug Administration (2010) Cetuximab (Erbitux) and panitumumab (Vectibix). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm. Accessed 29 Mar 2010
10. European Medicines Agency (2007) Questions and answers on the marketing authorisation for Vectibix. http://www.emea.europa.eu/pdfs/human/opinion/40511307en.pdf. Accessed 29 Mar 2010
11. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S et al (2010) Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820
12. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577
13. Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M et al (2011) The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol 41:165–171
14. Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C et al (2014) Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRA wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 34:1967–1973
15. Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S et al (2012) Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p. G13D mutation treated with cetuximab + irinotecan. Jpn J Clin Oncol 42:1146–1151
16. Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, et al (2016) Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. J Clin Oncol 34:2258–2264